Physician profile
Mark Durden
NPI 1518087907
$4,736.78
in general payments reported to CMS, 2019-2025
16 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $38.29 · 2021: $200 · 2022: $273 · 2023: $693 · 2024: $1,604 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,675 · Education: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,675.07 |
| Education | $289.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,285.66 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $1,280.98 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $493.37 | 2019-2025 | Ingrezza |
| Abbvie INC. | $418.56 | 2022-2025 | Vraylar |
| Vanda Pharmaceuticals INC. | $310.43 | 2024-2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $258.41 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $158.85 | 2024-2025 | Caplyta |
| Alkermes, INC. | $141.19 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Sunovion Pharmaceuticals INC. | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $112.01 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $69.68 | 2022-2025 | Abilify Asimtufii |
| Indivior INC. | $34.96 | 2024 | Perseris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.98 | 2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $13.96 | 2025 | |
| Allergan, INC. | $12.23 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $2.51 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Durden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.